Policy / Pricing Regeneron cuts White House pricing deal, offers new gene therapy for free Pharmaceutical TechnologyThis White House deal will see Regeneron offer all its new medicines at "MFN prices", while providing Otarmeni for free to eligible patients.Policy / PricingGene Therapy PlatformRead full story pharminent April 24, 2026 (Last updated: April 24, 2026) Pharmaceutical Technology This White House deal will see Regeneron offer all its new medicines at “MFN prices”, while providing Otarmeni for free to eligible patients. Policy / PricingGene Therapy PlatformRead full story Post navigation Previous: Cumberland to sell drug portfolio to Apotex for $100mNext: Cardiometabolic trials: Using expertise to turn complexity into robust results Related Stories Policy / Pricing Mid-cap biotechs join Trump’s latest round of drug pricing deals pharminent September 1, 2026 Policy / Pricing MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones pharminent August 27, 2026 Policy / Pricing MFN affecting Swiss medicines access, says Interpharma pharminent August 13, 2026